CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 57 target
Drug / intervention
Androgen Deprivation Therapy (ADT) +1 moredrug
Likely dose
Not stated in record
Key inclusion· 8
  • ✓Intermediate-risk prostate cancer (favorable or unfavorable subtypes)
  • ✓No mpMRI evidence of extra-prostatic extension or seminal vesicle invasion
  • ✓Chosen focal therapy for prostate cancer treatment
  • ✓Confirmed non-metastatic disease with appropriate staging imaging
Key exclusion· 8
  • ✕Prior or current prostate cancer therapies (biologic, chemotherapy, hormone, radiotherapy, or surgery)
  • ✕Pelvic radiation, chemotherapy or immunotherapy within 6 months for other malignancy
  • ✕Locally advanced, nodal, or metastatic prostate cancer
  • ✕Unfit for pelvic mpMRI scanning

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05790213
NCT05790213Phase 2RecruitingOn Track
CompareCT.gov

Phase II Trial of Focal Prostate Ablation Combined With Androgen Deprivation Therapy for Prostate Cancer Treatment

University of Chicago·interventional·Posted Mar 30, 2023·Updated Jun 16, 2026

In Brief

A Phase 2 clinical trial evaluating Androgen Deprivation Therapy (ADT) and Focal prostate ablation (focal therapy) for Prostate Cancer. Currently recruiting, targeting 57 participants across 1 site.

Detailed Summary

The purpose of this research is to gather information on the safety and effectiveness of combining focal prostate ablation therapy ((aka Focal Therapy, a surgical procedure) and androgen deprivation therapy (hormone therapy).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2Recruiting
202420252026202720282029
First PostedMar 30, 2023
Enrollment StartMay 5, 2025
Primary CompletionDec 18, 2028
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 3.3 years agoPrimary completion in 2.5 years

Arms & Interventions

Treatment Armexperimental

Participants will receive Androgen deprivation therapy (ADT) followed by Focal prostate ablation (focal therapy)

Drug: Androgen Deprivation Therapy (ADT)Procedure: Focal prostate ablation (focal therapy)

Interventions

Androgen Deprivation Therapy (ADT)drug

ADT will be given for 3 months. Participants will receive a standard ADT as chosen by their study doctor.

Focal prostate ablation (focal therapy)procedure

Focal prostate ablation (focal therapy) is a surgical procedure to destroy cancer cells by destroying a portion of the prostate instead of the whole prostate.